Cilgavimab and tixagevimab as pre-exposure prophylaxis in vaccine non-responder kidney transplant recipients during a period of prevalent SARS-CoV-2 BA.2 and BA.4/5 variants-a prospective cohort study (RESCUE-TX).
Reindl-Schwaighofer R, Heinzel A, Raab L, Strassl R, Herz CT, Regele F, Doberer K, Helk O, Spechtl P, Aschauer C, Hu K, Jagoditsch R, Reiskopf B, Böhmig GA, Benka B, Mahr B, Stiasny K, Weseslindtner L, Kammer M, Wekerle T, Oberbauer R.
Reindl-Schwaighofer R, et al. Among authors: mahr b.
EBioMedicine. 2024 Nov;109:105417. doi: 10.1016/j.ebiom.2024.105417. Epub 2024 Oct 22.
EBioMedicine. 2024.
PMID: 39442367
Free PMC article.